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Transcatheter aortic valve replacement
A B S T R A C T
Background: The eﬀects of surgical aortic valve replacement versus transcatheter aortic valve replacement on
endothelial function are unknown. We investigated the eﬀects of surgical and transcatheter aortic valve re-
placement on early and 90-day endothelial function measured by brachial ﬂow mediated dilation and apoptotic
rate in the human umbilical vein endothelial cells in patients with signiﬁcant aortic stenosis, intermediate risk of
surgery, and no coronary artery disease.
Methods: We conducted a prospective observational case control single-blind study at a single tertiary center.
Endothelial function was measured at baseline, early post-procedure (4 days), and follow-up (90 days). A blood
pressure cuﬀ was used to elicit reactive hyperemia for measuring brachial wall shear stress and ﬂow mediated
dilation. The apoptosis rate was observed in the human umbilical vein endothelial cells after 48-h incubation
with 20% serum from patients. The rate of apoptosis was assessed by determining the number of annexin V and
propidium iodide positive cells by ﬂow cytometry.
Results: Early post-procedure ﬂow dilation was signiﬁcant lower in the surgical group (p < 0.003). At follow-
up, both groups showed incremental increases in ﬂow mediated dilation. Surgical group apoptotic rate did not
signiﬁcantly change, while transcatheter apoptotic rate steadily decreased, suggesting a trend toward improved
endothelial function.
Conclusions: The data suggest that conventional surgical aortic valve replacement may be associated with an
early and transient decrease in endothelial function, likely due to the use of cardio-pulmonary bypass.
1. Introduction
Aortic stenosis (AS) aﬀects not only the left ventricle but also vas-
cular and endothelial function [1]. Patients with endothelial dysfunc-
tion have an increased risk of cardiovascular events [2]. Yet, the in-
ﬂuence of conventional surgical aortic valve surgery (SAVR) with the
aid of cardiopulmonary bypass (CPB) and cardioplegic myocardial
protection versus transcatheter aortic valve replacement (TAVR) on
endothelial function is unknown [3]. TAVR is indicated in high-risk
patients, but growing evidence suggests that a percutaneous approach
may be equally beneﬁcial for intermediate-risk patients [4]. Technique
superiority is judged based on standard outcomes such as mortality,
morbidity, and long-term freedom from reintervention; however, novel
markers of hemodynamic performance such as ﬂow-mediated dilation
(FMD) and apoptotic rate in the human umbilical vein endothelial cells
(HUVECs) as a measure of endothelial dysfunction are increasing in
popularity [5,6]. The non-invasive assessment of endothelial function
can be performed peripherally at the level of the brachial artery, by
measuring changes in artery diameter induced after an increase in the
blood ﬂow (“reactive hyperemia”). This technique is conventionally
named “ﬂow-mediated vasodilation”. This process has been validated in
clinical research, both in the ischemic and non-ischemic setting [3]. It is
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also believed that serum from dysfunctional endothelium may cause
apoptotic death in the HUVECs [3,6].
Therefore, the aim of this study was to evaluate the eﬀects of SAVR
and TAVR on early and late (90-day) endothelial function in patients
with signiﬁcant AS and intermediate risk for surgery.
2. Material and methods
The study was a prospective observational case control single-blind
design conducted at a single tertiary center in Italy. We screened all
patients with prevalent AS and intermediate risk for surgery. Risk was
estimated based on the risk model developed by the Society of Thoracic
Surgeons (STS; a score of 4–8%) [4,7]4. Patients with a STS risk
score< 4.0% were also eligible if they had additional comorbidities
that were not represented in the risk model. We excluded patients with
signiﬁcant coronary disease, previous coronary artery bypass grafting
and percutaneous angioplasty, and a need for concomitant procedures.
The Heart Team selected SAVR or TAVR for each patient after the
evaluation of preoperative investigations including coronary angio-
graphy, transthoracic echocardiography, chest radiography, laboratory
test results, and CT scanning to evaluate peripheral access. FMD and
transthoracic echocardiography were performed at baseline and at 4
and 90 days post-procedure. Apoptotic rate of HUVECs was obtained in
10 patients for each group at the same time point.
The study was conducted in accordance with the Declaration of
Helsinki and the study protocol was reviewed and approved by the
University of *** Institutional Review Board and registered as
EndoTAVI (SN 350/15). The requirement for patient consent was
waived.
2.1. SAVR
Median sternotomy was performed under general anesthesia.
Heparin was administered and followed by the institution of normo-
thermic CPB. Antegrade normo-thermic potassium-enriched cardio-
plegia was administrated after cross clamping. Next, accurate dec-
alciﬁcation of the native annulus was performed and, after sizing, a
tissue valve (Mosaic™, Medtronic, USA) was implanted with single su-
tures. Trans-esophageal echocardiography was used to check for para-
valvular leaks. All patients received aspirin (100mg) from day 1 after
surgery. All procedures were performed by a single surgeon (M.M.).
2.2. TAVR
All patients underwent transfemoral valve placement. Patients re-
ceived aspirin (100mg) and clopidogrel (≥300mg) before the proce-
dure, heparin during the procedure, and post-procedural aspirin (in-
deﬁnitely) and clopidogrel (minimum 1 month post-procedure).
Procedures were performed under local anesthesia with a mild an-
algesic and sedative regimen. The percutaneous puncture site was
closed with suture-based closure device (1 Prostar XL or 2 ProGlide
systems, Abbott Vascular Inc.). The Medtronic CoreValve Evolut R with
inLine Sheath EnVeo R delivery catheter (Medtronic Inc., Minneapolis,
Minnesota) was used in all cases. Events were deﬁned in accordance
with the Valve Academic Research Consortium-2 (VARC-2) [8]. Im-
plantation depth was measured on angiographic images and correct
implantation was deﬁned as a depth ≤6mm below the annulus plane;
depths> 6mm were considered to be low implantations [9]. Post-
procedural aortic regurgitation severity was assessed on angiography in
accordance with the Sellers classiﬁcation [10]. All procedures were
performed by a single operator (A.M.).
2.3. FMD for the assessment of endothelial function
FMD was measured as previously described [11]. Patients continued
medication during FMD. Brieﬂy, the probe was positioned 4–5 cm
above the elbow of the patient in a supine position to obtain a long-axis
view projection of the brachial artery. After a 60-s resting period, the
sphygmomanometer cuﬀ was placed distally to the imaging transducer
at the forearm level and inﬂated to 250mmHg for 300 s. Rapid deﬂa-
tion of the blood pressure cuﬀ was then performed to induce a brief
increase in blood ﬂow (reactive hyperemia) and resulting increase in
shear stress for dilatation of the brachial artery. Acquisitions of dia-
meter and ﬂow velocity were continued for 300 s. Normal maximum
speeds were 50–70 cm/s and reactive hyperemia was calculated as the
ratio of the maximal velocity during reactive hyperemia to the maximal
velocity at baseline [12]. The maximum FMD recovery value was cal-
culated as the ratio of the change in diameter (maximum− baseline) to
the baseline value.
FMD studies were performed using high-resolution ultrasonography
(Philips Sonos 5500) integrated with an image analysis system certiﬁed
by the National Research Council of Pisa (QUIPU, Cardiovascular suit,
IT), (positivity test value was set < 5%). All ultrasound examinations
were performed by the same physician (F.D.) or under her direct su-
pervision in order to reduce variability. Data analyses were conducted
oﬀ-line after study completion by 2 operators (M.C. and P.L.) who were
blinded to patient treatment allocations. Intra-observer reliability was
calculated for determining FMD. It was assumed that reduced ﬂow
mediated dilation value was associated to a decreased endothelial
function.
2.4. Brachial wall shear stress (BWSS) calculation
The increase in wall shear stress represented the stimulus for FMD.
Flow was calculated as π×(diameter ÷ 2)× 2× ﬂow velocity (V).
BWSS was calculated as 8× μ×(V÷ diameter), where blood viscosity
(μ) was assumed to be constant at 0.035 dyne/s/cm [13,14].
2.5. Cell culture
Endothelial function was also determined by assessing the rate of
apoptosis HUVECs after 48-h incubation with 20% serum from patients
as previously reported [15,16]. Brieﬂy, the rate of apoptosis was as-
sessed by determining the number of annexin V and propidium iodide
positive cells with ﬂow cytometry. Apoptosis rate was expressed as
percentage (%) of positive cells as compared to the total number of
cells. Analyses were performed at the Department of Morphology,
Surgery and Experimental Medicine University of Ferrara, (It). Apop-
totic rate of HUVECs was obtained in 10 patients for each group at the
same time point.
2.6. Primary and secondary outcome
The primary outcome was endothelial function assessed as FMD and
apoptotic rate in the HUVECs values at: a) baseline (pre-op), b) early
after surgery (post-operative day 4), and c) at follow-up (post-operative
day 90). Secondary outcomes included relevant in-hospital and follow-
up events.
2.7. Statistical analysis
The normality of each variable distribution was tested with the
Shapiro–Wilk test. Normally distributed variables were reported as the
mean ± standard deviation or median (interquartile range).
Categorical variables were reported as the number (percentage).
Intergroup comparisons of unpaired data were performed with 2-tailed
Student t tests for continuous variables or χ2 tests for categorical
variables. Correlations were explored with Pearson's product moment
correlation. Mann Whitney U tests were used to compare results at
single time points (baseline, early, and follow-up) and mixed models
were used to detect repeated measures diﬀerences between groups.
FMD values are presented as geometric mean ratios (GMRs). Type I
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error was signiﬁcant if < 0.05. An interclass correlation coeﬃcient
was used to calculate the level of agreement between operators for
calculating FMD. All analyses and data modeling were performed using
R-project (R Core Team 2013, Vienna, Austria; http://www.R-project.
org/) and the following package: pwr, aov, stats, and ggplot2 for data
visualization.
3. Results
From November 2015 to September 2017, 60 patients with AS sa-
tisﬁed the study eligibility criteria and underwent conventional SAVR
(n = 30) or TAVR (n = 30) at *** Hospital, *** Care & Research in ***,
Italy. Patients in the TAVR group were at higher risk for surgery as
calculated by STS score than those in the SAVR group (SAVR vs. TAVR,
4.2 ± 0.6 vs. 6.1 ± 1.8, p = 0.04; Table 1). Procedural details for
each group are shown in Table 2.
3.1. In-hospital outcome and follow-up
One patient died during the transcatheter procedure after ventricle
perforation followed by unsuccessful sternotomy and surgical correc-
tion. There was no in-hospital mortality in the SAVR group. Patient
outcomes are summarized in Supplemental Table 1. At 90-day follow-
up (100% compliance), there were 2 deaths related to cardiac causes in
the TAVR group and no deaths in the SAVR group.
3.2. Flow mediated dilation
Patients in the TAVR group had signiﬁcantly lower FMD at baseline
than those in the SAVR group (SAVR vs. TAVR, 6.4 ± 0.7 vs.
5.5 ± 0.4, p < 0.0001). At early evaluation (day 4), FMD was sig-
niﬁcantly lower in the SAVR group than in the TAVR group (4 ± 0.9
vs. 5.4 ± 0.4, p < 0.003). Both groups showed incremental increases
in FMD at follow-up (day 90), but FMD remained higher in the SAVR
than in the TAVR group (6.6 ± 0.7 vs. 5.9 ± 0.5, p < 0.003 (Fig. 1A,
Supplemental Table 2).
FMD was not signiﬁcantly increased at follow-up compared to
baseline in either group (SAVR: 6.4 ± 0.7 vs. 6.6 ± 0.7, p= 0.32;
TAVR: 5.5 ± 0.4 vs. 5.9 ± 0.5, p= 0.54). Overall, FMD was 4%
higher in the TAVR population (Fig. 1B, density plot; GMR [SAVR/
TAVR]= 0.96, 95% conﬁdence interval= 0.33–1.74, p < 0.001). The
interclass correlation coeﬃcient for operator agreement was 0.92
(variation 2.8%).
3.3. Brachial wall shear stress
In the SAVR group, there were signiﬁcant correlations between FMD
and peak shear stress at baseline (r= 0.92, p < 0.001), early evalua-
tion (r= 0.81, p < 0.001), and follow-up (r= 0.95, p < 0.001).
Table 1
Baseline characteristics.
SAVR (n= 30) TAVR (n= 30) Overall (N= 60) p-value
Age, years 80 ± 5.2 82.3 ± 6.1 81.1 ± 5.6 0.17
Male sex no. (%) 16 (53.3) 10 (33.3) 26 (43.3) 0.43
BMI 26.6 ± 5.1 27.5 ± 6.2 27 ± 5.6 0.48
STS risk score 4.2 ± 0.6 6.1 ± 1.8 5.1 ± 1.2 0.04
NYHA III or IV no. (%) 19 (63.3) 21 (70) 29 (66.6) 0.96
Cerebral vascular disease no. (%) 4 (13.3) 7 (23.3) 11 (36.6) 0.61
Peripheral vascular disease no. (%) 11 (36.6) 14 (46.6) 25 (41.6) 0.79
Diabetes mellitus no. (%) 15 (50) 25 (83.3) 40 (66.6) 0.3
COPD no. (%) 6 (20) 10 (33.3) 16 (26.6) 0.54
Creatinine > 2mg/dl no. (%) 2 (6.6) 5 (16.6) 7 (11.6) 0.5
Atrial ﬁbrillation no. (%) 2 (6.6) 4 (13.3) 6 (10) 0.72
Permanent pacemaker no. (%) 1 (3.3) 2 (6.6) 3 (5) 1
5-m walk test time > 7 s no. (%) 1 (3.3) 5 (16.6) 6 (10) 0.25
Left ventricle ejection fraction % 50.5 ± 7.1 52 ± 5.2 51.2 ± 6 0.72
Pulmonary pressure > 45mmHg no. (%) 1 (3.3) 3 (10) 4 (6.6) 0.65
Medication no. (%)
Coumadin 2 (6.6) 4 (13.3) 6 (10) 0.72
Aspirin 28 (93.3) 27 (90) 55 (91.6) 1
β-adrenergic antagonist 29 (96.6) 27 (90) 56 (93.3) 0.99
ACE inhibitor/ARB 15 (50) 18 (60) 33 (55) 0.83
Statin 29 (96.6) 28 (93.3) 57 (95) 1
Data are expressed as the mean ± standard deviation or number (percentage). ACE, angiotensin converting enzyme; ARB, angiotensive receptor blocker; BMI, body
mass index; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association scale; SAVR, surgical aortic valve replacement; STS, Society of
Thoracic Surgery; TAVR, transcatheter aortic valve replacement.
Table 2
SAVR and TAVR procedural data.
Tissue, Mosaic (n= 30)
Cardio-pulmonary bypass, min 70.8 ± 15.4
Cross clamp time, min 52.5 ± 12.2
Operation time, min 180 ± 52.1





≥ Moderate paraprosthetic leak 0
Evolute R (n = 30)
Device success no. (%) 29 (99)
Procedural time, min 122 (70)
Fluoroscopy time, min 32 ± 10.2
Contrast media, ml 190 (70)




Pre-dilatation no. (%) 5 (16.6)
Post-dilatation no. (%) 14 (46.6)
Valve malpositioning no. (%) 0
Coronary obstruction no. (%) 0
Cardiac tamponade no. (%) 1 (3.3)
Vascular access site complication no. (%) 4 (13.3)
≥ Moderate paraprosthetic leak no. (%) 4 (13.3)
Data are expressed as the mean ± standard deviation or number (percentage).
SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve re-
placement.
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Similarly, signiﬁcant correlation was observed in the TAVR group
(baseline r= 0.68, p < 0.001; early evaluation r= 0.72, p < 0.001;
and follow-up r= 0.49, p < 0.006) (Supplemental Table 2, Fig. 2A–C).
3.4. Apoptotic rate HUVECs
Baseline apoptosis rate was higher in the TAVR group: 9.3 ± 2.5 vs
9.9 ± 1.6%, (SAVR vs TAVR respectively) but not statistically sig-
niﬁcant (p=0.3). There was also no signiﬁcant diﬀerence at early (day
4) and late (day 90) evaluation between groups 8.4 ± 1.8 vs
8.9 ± 1.9%, p=0.3; and 10.2 ± 2.6 vs 8.9 ± 1.7%, p= 0.5, SAVR
vs TAVR respectively (Fig. 3 A). Overall there was a tendency toward
reduced apoptotic rate in the TAVR group (geometric mean ratio (GMR)
1.01, 95% CI (0.94, 1.27), p= 0.5) (Fig. 3B).
4. Discussion
The present study found that patients who underwent SAVR showed
a signiﬁcant decrease in endothelial function (FMD) early after the
procedure; however, reduced FMD was not associated with a poorer
Fig. 1. A). Flow-mediated dilation (FMD, %),
SAVR vs. TAVR: baseline, 6.4 ± 0.7 vs.
5.5 ± 0.4, p < 0.0001; day 4, 4.0 ± 0.9 vs.
5.4 ± 0.4, p < 0.003; follow-up, 6.6 ± 0.7 vs.
5.9 ± 0.5, p < 0.003, B). Geometric mean
ratio (SAVR/TAVR)=0.96, 95% conﬁdence
interval= 0.33–1.74, p < 0.001. SAVR, sur-
gical aortic valve replacement; TAVR, trans-
catheter aortic valve replacement.
Fig. 2. Correlation between brachial wall shear stress (BWSS) and ﬂow-mediated dilation (FMD) in the SAVR and TAVR groups at (A) baseline, (B) day 4, and (C)
follow-up (90 days). SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.
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outcome. Marginal but non-signiﬁcant increases FMD were observed in
both groups at 90 days follow-up. We also identiﬁed positive correla-
tions between BWSS and FMD in both groups.
SAVR apoptotic rate did not signiﬁcantly change, while TAVR
apoptotic rate steadily decreased, suggesting a trend toward improved
endothelial function; however that was not signiﬁcant.
To the best of our knowledge, this is the ﬁrst study to investigate
endothelial function in patients undergoing SAVR and TAVR.
Impaired endothelial function has been associated with an increased
risk of future cardiovascular events and a decreased probability of
survival [17]. The majority of previous studies focused on a relationship
between atherosclerosis and endothelial function, and few of these
studies have been conducted in patients with AS [17]. A convincing
body of evidence suggests that degenerative AS represents a form of
atherosclerotic disease [18]; importantly, this study included in-
dividuals with intermediate risk for surgery and no signiﬁcant or pre-
viously treated coronary ischemic disease in order to minimize the in-
terference of ischemic disease and other comorbidities with endothelial
function.
Only 4 previous studies have investigated the eﬀects of SAVR on
endothelial function. Our results are consistent with those of Morelos
et al., who reported transient systemic endothelial dysfunction after
SAVR; however, this study included patients with coronary disease and
AS [19]. Our ﬁndings are also in line with Chenevard et al. [20], who
did not report any beneﬁcial eﬀects of SAVR on endothelial function at
5.3 months after surgery. Yet, this study only included 15 patients. In
contrast, Takata et al. [21] reported signiﬁcant improvements in FMD
early after SAVR, but the study was limited by a small cohort of only 20
patients. No diﬀerences were found in indices of endothelial/vascular
function after AVR at follow-up (2.4 months) in another study [22].
Taken together, there is weak evidence associating SAVR with im-
provements in FMD.
It is accepted that serum from patients with dysfunctional en-
dothelium can determine apoptosis in HUVECs [6,23]. Although we did
not ﬁnd statistically signiﬁcant diﬀerence in between groups, it seemed
that serum from TAVR exerts less apoptosis rate, yet given the small
sample size conclusions cannot be drawn.
We speculate that an early decrease in endothelial function after
SAVR may have been related to the use of the CPB. Decreased nitric
oxide bioavailability as indicated by decreases in the expression of
endothelial nitric oxide synthase following CPB may reduce endothelial
reactivity [24]; indeed, various studies have demonstrated an associa-
tion between CPB or the duration thereof and nitric oxide consumption
[24]; the latter association may correspond not only to hemolysis due to
the surgical procedure and CPB, but also due to the use of cell saver
devices, the transfusion of stored blood, and other factors [24]. Several
studies have demonstrated the deregulation of vascular resistance after
CPB. Magder et al. [25] described higher systemic vascular resistances
with deregulation up to 18 h post-procedure. In our surgical case series,
we observed a reduction in FMD at 4 days post-procedure; however, we
Fig. 3. A). Apoptosis rate (%), SAVR vs. TAVR: baseline, 9.3 ± 2.5 vs 9.9 ± 1.6%; day 4, 8.4 ± 1.8 vs 8.9 ± 1.9%, p=0.3; follow-up, 10.2 ± 2.6 vs 8.9 ± 1.7,
p= 0.5. B). Geometric mean ratio (SAVR/TAVR)=1.01, 95% CI (0.94, 1.27), p= 0.5. SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve
replacement.
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did not measure vascular resistances. Of note, no patients were re-
ceiving intravenous inotrops or vasoconstrictors at the time of FMD
analysis. Therefore, the transient side eﬀects of CPB may explain early
reductions in FMD after SAVR [26].
Few studies have investigated the relationship between TAVR and
systemic endothelial function using non-invasive methods such as FMD
and determination of circulating endothelial microparticles [18]. Jung
et al. [27] demonstrated a positive decline in circulating endothelial
and platelet microparticles as result of diminished endothelial stress
after TAVR. Interestingly, the TAVR procedure itself is frequently as-
sociated with vascular or peri-procedural complications that ultimately
lead to a systemic early inﬂammatory response and associated increases
in endothelial microparticles [28]. Horn et al. demonstrated that the
endothelial function was signiﬁcantly improved after TAVR, as wit-
nessed by higher FMD values and lower levels of circulating endothelial
microparticles compared to baseline [13]. Interestingly, the abrupt in-
crease in cardiac output that follows the TAVR procedure may expose
the vascular endothelium to rapid changes in mechanical forces, which
aﬀect vascular tone and endothelial activation but may also be asso-
ciated with markers of tissue injury and inﬂammation [29].
An important strength of this study is its novelty in comparing the
eﬀects of SAVR and TAVR on FMD and laboratory markers in the early
and late post-surgical periods. The study enrolled a series of patients
who were at intermediate risk with no coronary disease in order to
separate AS from atherosclerotic disease and reduce baseline hetero-
geneity. Additionally, FMD evaluations were conducted blindly (oﬀ-
line) by 2 independent operators.
We acknowledge several study limitations. Since we recruited pa-
tients at intermediate risk for surgery where indication for treatment
was reached after heart team discussion, randomization was not pos-
sible. Perhaps the biggest study limitation is the small sample size.
However, we aimed to investigate the eﬀect of both treatments on
speciﬁc markers of endothelial function and no clinical correlation was
anticipated. Also the length of follow up was limited.
The apoptosis rate in the HUVECs was carried out as subgroup
analysis hence was not possible to explore potential correlation be-
tween FMD and apoptotic rate. We could not separate the eﬀects of
medications from those of AVR on endothelial function in our study.
Also, TAVR group was taking in addition to aspirin clopidogrel that
might be a confounding factor in our study.
5. Conclusion
Conventional SAVR was associated with a transient decrease in
endothelial function in the early post-operative period, probably due to
the use of CPB.
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